EDITORIAL

Troponin Elevation After Ischemic Stroke and Future Cardiovascular Risk: Is the Heart in the Right Place?

Santosh B. Murthy, MD, MPH

Our understanding of the intricate relationship between the heart and the brain has evolved beyond the prevailing paradigm where cardiac mechanisms cause brain injury, to now include a bidirectional interaction, where an acute derangement of one organ system adversely affects the other. Acute brain injury in the form of an ischemic or hemorrhagic stroke is a trigger for myocardial injury, often referred to as neurocardiogenic syndromes, which can range from asymptomatic troponin elevations to symptomatic myocardial ischemic injury, and even symptomatic heart failure such as Takotsubo cardiomyopathy. Large case series evaluating factors associated with neurocardiogenic syndromes have implicated stroke severity and location of the infarct as key factors. Additionally, myocardial injury portends poor outcomes, and is independently associated with severe disability and death after stroke. Given that neurocardiogenic syndromes encompass a wide range of cardiac abnormalities, it is unclear if each subtype adversely affects stroke outcomes. Emerging evidence suggests that one neurocardiogenic syndrome, Takotsubo cardiomyopathy, results in both, a short- and long-term risk of major adverse cardiovascular events, ischemic stroke, and death, regardless of the inciting trigger. However, whether troponin elevation also results in a similarly higher risk of future cardiovascular events is poorly studied.

In this context, the study by Scheitz and colleagues in this issue of the Journal of the American Heart Association (JAHA) assumes significance. The authors performed a prospective, observational study of 562 patients with a first-ever stroke, with longitudinal follow up. The exposure was the level of high sensitivity-cardiac troponin T, obtained within 7 days of stroke symptom onset, and dichotomized based on a cut-off of 14 ng/L (the upper reference limit). The primary outcome was a major vascular event, defined as a composite of any stroke (ischemic or hemorrhagic), myocardial infarction, and all-cause mortality, while the secondary outcome was ischemic stroke alone. Cox regression analyses showed that an elevated high sensitivity troponin was associated with a 2-fold heightened risk of a major vascular event, compared with patients without. Surprisingly, there was no relationship with recurrent ischemic stroke. The authors should be congratulated on this important study which has several strengths.

Key Words: Editorials ■ ischemic stroke ■ myocardial injury ■ stroke ■ troponin

See Article by Scheitz et al.
Although no such association was observed, independently increases this risk after an incident stroke, it is important to delineate if myocardial injury prior to stroke is a significant risk factor for recurrent stroke as a stand-alone secondary outcome. Given that a strategy proven to decrease cardiovascular risk, including lack of data on antithrombotic medication initiation or resumption after stroke, a treatment strategy proven to decrease cardiovascular risk. Moreover, the study examined baseline comorbidities, and did not account for changes in risk factors or new diagnoses over time. Furthermore, the study did have information on stroke subtype, which may be relevant to the degree of myocardial injury. It would also be interesting to note the differences in troponin elevation in patients with and without occult sources of cardiac embolism such as atrial fibrillation, cardiac thrombus, and severe heart failure.

Nevertheless, the results of this study raise some intriguing points. First, isolated transient myocardial injury after stroke is not a benign finding despite the normalization of troponin values, similar to Takotsubo cardiomyopathy. Second, the question that arises is whether myocardial injury after stroke is a chicken or egg phenomenon? Our current state of literature does not allow this temporal distinction. Transient troponin elevation, a manifestation of neurocardiogenic injury can occur in up to half of all stroke patients and is believed to be mediated by a catecholamine surge and microvascular coronary endothelial dysfunction, among other mechanisms, which ultimately leads to myocardial remodeling weeks to months after the initial injury. On the other hand, myocardial injury in some cases, may be a consequence of an underlying cardiac embolic source and may provide clues to the stroke mechanisms particularly in the absence of occult causes. For instance, in a prospective cohort study of 1234 patients with ischemic stroke, early positive troponin was associated with a cardioembolic source, and did not correlate with stroke severity. Since nearly a third of strokes have no identifiable cause, a subset generally referred to cryptogenic stroke or embolic stroke of undetermined source (ESUS), an improved understanding of myocardial injury may help guide interpretation of cardiac biomarker derangements in the clinical setting. Clinicians have increasingly recognized the role of non-traditional cardiac sources of emboli under the ESUS construct, with emphasis on atrial cardiopathy and silent myocardial infarction. This has spurred a new line of investigation evaluating parameters on cardiac evaluations, otherwise neglected in prior years, including atrial chamber dilation on echocardiography and p-wave terminal force or Q wave on electrocardiography. Along similar lines, re-exploration of serum biomarkers of cardiac injury, which is relatively inexpensive and perhaps more feasible, are warranted.

Third, the severity of myocardial injury after stroke may help in stratifying the risk of recurrent cardiovascular events, and tailoring therapies. Future studies should therefore aim to incorporate objective measure of cardiac dysfunction in ascertaining the cardiovascular risk akin to the CHA2DS2-VASC score for atrial fibrillation. Finally, with the emergence of direct oral anticoagulants, the role of anticoagulation is being explored in non-traditional embolic strokes, such as ESUS. Current American Heart Association guidelines recommend antiplatelet therapy for secondary stroke and cardiovascular risk prevention, in the absence of occult indications for anticoagulation. Whether antiplatelet therapy alone is adequate in the presence of myocardial injury is, however, unclear. In a secondary

| Study (Year) | Design     | Sample Size | Exposure          | Outcomes                                      | Effect Size HR/OR (95% CI) |
|------------|------------|-------------|-------------------|-----------------------------------------------|-----------------------------|
| Stahrenberg (2012) | Prospective | 197         | HS-troponin       | MACE†+revascularization+CHF hospitalization   | 3.2 (N/A)                  |
| Raza (2014) | Retrospective | 200         | Cardiac troponin I | MACE† (included coronary revascularization; no stroke events) | 9.8 (2.4–39.4)             |
| Ahn (2019)  | Prospective | 1092        |                   | MACCE*                                        | 2.8 (1.8–4.3)              |
| Schetz (2021) | Prospective | 562         | HS-troponin       | MACCE*                                        | 2.0 (1.3–3.3)              |

CHF indicates congestive heart failure; CI, confidence interval; HR, hazard ratio; HS, high sensitivity; MACE, major adverse cardiovascular events; MACCE, major adverse cerebrovascular and cardiovascular events; N/A, not available; and OR, odds ratio.

*MACCE included any stroke, myocardial infarction, and cardiovascular death.

†MACCE included myocardial infarction and cardiovascular death.
analysis of the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, among patients with stable cardiovascular disease, low-dose rivaroxaban plus aspirin was associated with fewer cardiovascular events,\(^{14}\) including large, significant reductions in cardioembolic strokes and ESUS.\(^{15}\)

Ongoing clinical trials such as ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) are examining the ideal antithrombotic strategy in patients with ESUS and atrial cardiopathy.\(^{16}\) Expanding these indications to other forms of myocardial injury may help shed light on the optimal strategies to mitigate the risk of subsequent cardiovascular events. Regardless, the present study brings to focus the complex interplay between the heart and the brain, and highlights the need for more such clinical studies to better delineate the clinical implications of the myocardial injury after stroke.

ARTICLE INFORMATION

Affiliation
Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY.

Sources of Funding
Dr Murthy reports funding from the NIH (K23NS105948).

Disclosures
Dr Murthy has received medicolegal consulting compensation.

REFERENCES

1. Sposato LA, Hliz MJ, Aspberg S, Murthy SB, Bahit MC, Hsieh CY, Sheppard MN, Scheitz JF. Post-stroke cardiovascular complications and neurogenic cardiac injury, JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:2768–2785. DOI: 10.1016/j.jacc.2020.10.009.
2. Scheitz JF, Nolte CH, Doehner W, Hachinski V, Endres M. Stroke-heart syndrome: clinical presentation and underlying mechanisms. Lancet Neurol. 2018;17:1109–1120. DOI: 10.1016/S1474-4422(18)30336-3.
3. Kerr G, Ray G, Wu O, Stott DJ, Langhorne P. Elevated troponin after stroke: a systematic review. Cerebrovasc Dis. 2009;28:220–226. DOI: 10.1159/000226773.
4. Templin C, Ghadiri JR, Diekmann J, Napp LC, Bataisou DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929–938. DOI: 10.1056/NEJMoa1406761.
5. Scheitz JF, Lim J, Broersen LHA, Ganeshan R, Hoo S, Sperber PS, Piper SK, Heuschmann PU, Audebert HJ, Nolte CH, et al. High-sensitivity cardiac troponin T and recurrent vascular events after first ischemic stroke. J Am Heart Assoc. 2021;10:e018326. DOI: 10.1161/JAHA.120.019326.
6. Ahn SH, Kim YH, Lee JS, Han JH, Kim SY, Kang DW, Kim JS, Kwon SJ. Troponin I levels and long-term outcomes in acute ischemic stroke patients. J Am Coll Cardiol. 2019;73:525–526. DOI: 10.1016/j.jacc.2018.11.022.
7. Raza F, Akhouri M, Sandhu P, Bhatt R, Bove AA. Elevated cardiac troponin in acute stroke without acute coronary syndrome predicts long-term adverse cardiovascular outcomes. Stroke Res Treat. 2014;2014:621650. DOI: 10.1155/2014/621650.
8. Stahrenberg R, Niehaus C-F, Edelmann F, Mende M, Wohlfahrt J, Wasser K, Seegers J, Hasenfuss G, Groschel K, Wachter R. High-sensitivity troponin assay improves prediction of cardiovascular risk in patients with cerebral ischaemia. J Neurosurg Psychiatry. 2015;84:479–487. DOI: 10.1136/jnnp-2012-303360.
9. Mohan KM, Wolfe GD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieble AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42:1489–1494. DOI: 10.1161/STROKEAHA.110.602615.
10. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Petto R, Buring J, Hennekens C, Kearney P, et al. Early elevated troponin levels after ischemic stroke suggests a cardioembolic source. Stroke. 2018;49:121–126. DOI: 10.1161/STROKEAHA.117.019395.
11. Yaghjii S, Chang AD, Ricci BA, Jayaraman MV, McTaggart RA, Hemendinger M, Narwal P, Dakay K, Mac Gory B, Cutting SM, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860. DOI: 10.1016/S0140-6736(09)60503-1.
12. Kamel H, Merkler AE, Ladecola C, Gupta A, Navi BB. Tailoring the approach to embolic stroke of undetermined source: a review. JAMA Neurol. 2019;76:855–861. DOI: 10.1001/jamaneurol.2019.0591.
13. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–2236. DOI: 10.1161/STR.0000000000000024.
14. Elkayoom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakowska O, Diaz R, Alings M, Lomn EM, Anand SS, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease: collaborative meta-analysis of individual participant data from randomised trials. Eur Heart J. 2014;35:2734–2742. DOI: 10.1093/eurheartj/ehu274.
15. Perera KS, Ng KKH, Nayar S, Catanese L, Dyal L, Sharma M, Connolly SJ, Yusuf S, Bosch J, Elkayoom JW, et al. Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the compass trial. JAMA Neurol. 2020;77:43–48. DOI: 10.1001/jamaneurol.2019.2894.
16. Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Broderick JP, Palesch YY, Meinerz C, Dillon C, Ewing I, Spilker JA, et al. The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods. Int J Stroke. 2019;14:207–214. DOI: 10.1177/1747493018799981.